Infinite scope for Infinity Pharmaceuticals Inc (NASDAQ:INFI)’s Sparks for Inspiration campaign
Infinity Pharmaceuticals Inc (NASDAQ:INFI) is observing a national Blood Cancer Awareness Month. It is joining healthcare providers, patients and patient organizations in raising public-awareness of various blood cancers. Another topic that is being highlighted is the need for constant research in novel methods of treatment. The company is launching the Sparks for Inspiration campaign for patients and well as their loved ones.
Right through September, INFI will encourage the submission of photos, illustrations and stories that honor family members, friends and loved ones who have been affected by blood cancer. For every submission that comes in, INFI will make a $10 donation to the LLS- Leukemia &Lymphoma Society. This is the largest voluntary health organization in the world and focuses solely on blood cancers.
The lead candidate
Infinity Pharmaceuticals Inc (NASDAQ:INFI) is currently developing a potent oral-inhibitor of (PI3K)-delta and PI3K-gamma. This will be used in the treatment of some blood cancers. The early phare-1 data has shown many encouraging signs of clinical-activity across a variety of blood cancers. The Director of the haematologic malignancies program, Ian Flinn, M.D., Ph.D said that he is very excited about being involved in this study and that he looks forward to the further-evaluation of this particular drug.
At the moment, the company is enrolling different patients in a Phase II study that has been designed to evaluate the efficacy and safety of IPI-145, its lead-candidate, for treating refractory-indolent non Hodgkin Lymphoma.
The study progress
The patients who have been enrolled in this particular study have now progressed within 6 months of having received their last therapy. In addition to this, a Phase 1B investigator sponsored trial has also been conducted using IPI-145 in patients who are suffering from B-Cell NHL, CLL and T-cell Lymphom. This treatment is given in combination with rituximab and bendamustine or both.